ON Partners, over the last few years, has collaborated with Niche and its CEO to grow its executive leadership team.
Neurotech Pharmaceuticals Makes New Appointment to Board of Directors
Neurotech Pharmaceuticals Names Robert Dempsey to Board of Directors
Neurotech Pharmaceuticals, a biotechnology company developing transformational, sight-saving therapeutics for the treatment of chronic eye diseases, recently appointed Robert Dempsey to the organization’s Board of Directors.
Dempsey is currently serving as the Chief Executive Officer and President at AsclepiX Therapeutics. With over two decades of domestic and international experience leading successful drug development, business transactions, and commercialization in the ophthalmic space, he will bring deep relationships with Key Opinion Leaders and comprehensive knowledge of the ophthalmic ecosystem to Neurotech. He has held a variety of leadership roles across commercial, business development, medical affairs, and venture-backed startups.
Most recently, Dempsey served as the Chief Executive Officer for TearClear, successfully leading the company through Series B financing and positive FDA engagement. Prior to that, he served as the Global Head of Ophthalmology at Shire, then Takeda, responsible for one of the top 10 largest biopharma M&A deals in 2019.
Dempsey earned his MBA and BS from Northeastern University. View his full bio from Neurotech Pharmaceuticals here.
Executive Search Partnership: Neurotech Pharmaceuticals
ON Partners partner Suzanne Zebedee is proud to have partnered with Neurotech Pharmaceuticals on this successful board placement. Review more of our recent board and C-level executive search placements in our Life Sciences and Health Executive Talent Report.
Neurotech Pharmaceuticals, Inc. is a biotechnology company developing transformational, sight-saving therapeutics for the treatment of chronic eye diseases. Its patented core technology platform, Encapsulated Cell Technology (ECT), is a genetically engineered implant that enables continuous delivery of protein drugs directly into the vitreous humor of the eye over an extended period. Neurotech is clinically studying its lead product candidate, NT-501, in a Phase 3 program to treat the orphan disease Macular Telangiectasia (MacTel) and in a Phase 2 study to treat Glaucoma. To learn more, visit www.neurotechusa.com.
About ON Partners
Since 2006, ON Partners is the only pure-play executive search firm building diverse C-level and board leadership teams. We rebuilt the institution of executive search for the way you work. Our approach includes present partners who engage with their clients from the first brief to the final decision, individually crafted solutions that are unique to each client, and an easier experience all around. Named by Forbes as one of America’s Best Executive Recruiting Firms and to the Inc. 500/5000 Lists nine times, ON Partners is consistently ranked among the top 20 retained executive search firms in the U.S.
Untraditional by Choice. Original by Design. Since 2006.
START YOUR JOURNEY WITH US TODAY.
If you want to create a new path – ON Partners knows how to help you get there.